Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment. - Wikidata - wikimedia - TriplyDB

Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.

Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.

http://www.wikidata.org/entity/Q41544958

about

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.Long-lasting corneal endothelial graft rejection successfully reversed after dexamethasone intravitreal implant Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema.Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema.A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema.Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenario Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

P2860

Q26775853-FB141E5A-1802-45D2-B46D-66F8215E3731 Q36018006-4C25B0CE-77BE-4876-953E-5604E515B77C Q36088928-6070E540-B115-45AC-9925-534CE85906CB Q41007892-CA8D31C1-881A-4CB2-A0D4-612DEDD88767 Q41250047-882665A7-B5C3-4B08-A80D-398C650E8EB4 Q47095285-C8F9E46D-678B-4047-BFFF-262E8C66A4E6 Q47230436-85BEA8A8-1D8E-4D52-B75F-E61C59B3022E Q50198182-6A69AD27-43B7-44FA-9370-3CD0B20E7791 Q50224380-D020F59A-0ECA-48CB-8129-D4192D4E8CD0 Q51503400-87E17A10-3622-4F97-BB18-4BA9F5AD096B Q57193051-9AD5E6D2-B093-43A2-8BCD-E6D5EEDB6247 Q58697579-1641F7C2-F8CC-410E-AE5A-ACAB2E03D451

P2860

Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.

http://www.wikidata.org/entity/Q41544958

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dexamethasone Intravitreal Imp ...... vitreal Bevacizumab Treatment.

@en

type

label

Dexamethasone Intravitreal Imp ...... vitreal Bevacizumab Treatment.

@en

prefLabel

Dexamethasone Intravitreal Imp ...... vitreal Bevacizumab Treatment.

@en

P1433

Q41544958-FEB33D52-D87F-438B-B3E9-C3327878C0E7

P1476

Q41544958-929D36D7-BEE4-45BF-B764-A7C375EE1414

P2093

Q41544958-678D7696-2558-4D5C-B696-8D22DC70719B

Q41544958-90CCCC95-5EFE-4FF1-8321-77AC895EB692

Q41544958-D46CCCC8-F028-4F9D-91DF-C28C4C8DAD18

P2860

Q41544958-01B56821-9C75-421A-8CF1-D84BAB3849EF

Q41544958-03EFF27F-6F4A-49C8-BD6E-C7B0C47DC0FF

Q41544958-20A9646D-EB57-4C10-920D-E825D4E63847

Q41544958-2B4F3E32-5564-4908-95FC-0DA0DE89E65C

Q41544958-2BEC2893-FD2F-43D4-89B6-381EB777DE43

Q41544958-40867225-419C-4D72-A87B-B3638042A170

Q41544958-5D015C51-1EF2-41D8-9213-0B48255D0B79

Q41544958-60F20269-8448-4013-9036-3ECFB288C522

Q41544958-62D3B991-8D0A-4DBB-890E-595CD4CA1341

Q41544958-6AE22F3E-2196-47B0-9FDB-DA8EDC79ADBF

P304

Q41544958-676BBC98-B3AE-47DB-B613-B7D969573D7E

P31

Q41544958-A5926C59-BD36-4B80-8A93-8F4D0D9DB5C9

P356

Q41544958-1A9F2BF8-8453-4200-B052-272B6C4FFB3A

P433

Q41544958-CD1BB4B8-5BFD-45E0-AD5D-F4A464CFA6F8

P478

Q41544958-80960FD0-8DE0-43F7-B205-5C8D6F8D3BC4

P577

Q41544958-A79DD36E-5A54-4799-8E51-E718DF841D91

P698

Q41544958-96FA7C36-486C-4A0A-A398-3AEEC4A8390E

P921

Q41544958-342622C3-2500-43CE-822B-131D71F9C046

Q41544958-D50202AA-0B14-4EFF-A3D0-5557F321896E

P356

02713683.2014.1002048

P1433

Current Eye Research

P1476

Dexamethasone Intravitreal Imp ...... vitreal Bevacizumab Treatment.

@en

P2093

Emre Güler

http://www.w3.org/2001/XMLSchema#string

Fatma Betül Gürağaç

http://www.w3.org/2001/XMLSchema#string

Yüksel Totan

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

Association of vitreous inflammatory factors with diabetic macular edema.

Diabetic macular edema: pathogenesis and treatment.

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group.

Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

P304

107-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/02713683.2014.1002048

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25610946

http://www.w3.org/2001/XMLSchema#string

P921